Document Type
Oral Presentation
Location
Oxford Conference Center - Auditorium
Start Date
8-4-2019 10:45 AM
End Date
8-4-2019 11:00 AM
Description
NCCIH was established in 1999 with a mandate to fund research on those practices considered outside the mainstream of western medicine. In the ensuing 20 years, NCCIH has supported a wide variety of research using many different complementary and integrative health approaches. Along the way we have learned a great deal about how best to support this research and how to get the most out of our investments. As a result, NCCIH has become much more thoughtful about how to fund clinical research as well as what sorts of biological outcomes are most relevant to our mission. This presentation will provide an overview focused on NCCIH investments in natural products research. This will include a retrospective of the clinical trials that were funded in our first 10 years, how those trials were perceived by various stakeholders, and how we have applied the lessons learned in our first two decades to our priorities for the future.
Recommended Citation
Hopp, Craig, "Session 2: "NCCIH Turns 20: What Have We Learned?"" (2019). Oxford ICSB. 2.
https://egrove.olemiss.edu/icsb/2019_ICSB/day1/2
Publication Date
April 2019
Session 2: "NCCIH Turns 20: What Have We Learned?"
Oxford Conference Center - Auditorium
NCCIH was established in 1999 with a mandate to fund research on those practices considered outside the mainstream of western medicine. In the ensuing 20 years, NCCIH has supported a wide variety of research using many different complementary and integrative health approaches. Along the way we have learned a great deal about how best to support this research and how to get the most out of our investments. As a result, NCCIH has become much more thoughtful about how to fund clinical research as well as what sorts of biological outcomes are most relevant to our mission. This presentation will provide an overview focused on NCCIH investments in natural products research. This will include a retrospective of the clinical trials that were funded in our first 10 years, how those trials were perceived by various stakeholders, and how we have applied the lessons learned in our first two decades to our priorities for the future.